Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.

Yonker LM, Swank Z, Gilboa T, Senussi Y, Kenyon V, Papadakis L, Boribong BP, Carroll RW, Walt DR, Fasano A

Critical care explorations18 Feb 2022Cited by 17 (Europe PMC)

PMID35211683PMCIDPMC8860335DOI10.1097/cce.0000000000000641PepBankPUB-35211683

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanCase report or seriesEfficacy outcome
Children with MIS-C receiving adjunctive larazotide had faster gastrointestinal symptom resolution than children receiving steroids and/or IVIG alone.
In plain wordsChildren with MIS-C receiving adjunctive larazotide had faster gut symptom resolution than those receiving steroids and/or IVIG alone.
Peptide
Larazotide
Outcome
DecreaseTime to gastrointestinal symptom resolution
Study
n = 26
Comparator
Steroids and/or IVIG alone
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
10 mcg/kg (maximum 500 mcg/dose), four times daily · oral · 21 daysAs given in this study (human).
Source sentences
Summary
When compared with 22 children with MIS-C receiving steroids and/or intravenous immunoglobulin therapy alone, larazotide-treated patients reported significantly improved time to resolution of gastrointestinal symptoms (p = 0.03),
4 context sentences(design, population, supporting numbers)
Summary · context
Children with MIS-C were treated with larazotide as an adjuvant to steroid/intravenous immunoglobulin therapy.
Summary · context
Outcomes were compared with children with MIS-C receiving steroids and/or IVIG therapy alone.
Summary · context
Four children with MIS-C, ages 3-17 years, were enrolled.
Summary · context
Patients were treated with open label larazotide 10 mcg/kg (maximum 500 mcg/dose) orally four times daily for 21 days.
Report a problemFND-3521168303
02HumanCase report or seriesEfficacy outcome
Children with MIS-C receiving adjunctive larazotide had faster Spike antigen clearance than children receiving steroids and/or IVIG alone.
In plain wordsChildren with MIS-C receiving adjunctive larazotide cleared Spike antigen faster than those receiving steroids and/or IVIG alone.
Peptide
Larazotide
Outcome
DecreaseTime to Spike antigen clearance
Study
n = 26
Comparator
Steroids and/or IVIG alone
Outcome group
Antiviral activity · Infection
Studied dose
10 mcg/kg (maximum 500 mcg/dose), four times daily · oral · 21 daysAs given in this study (human).
Source sentences
Summary
and time to clearance of Spike antigenemia (p = 0.04),
4 context sentences(design, population, supporting numbers)
Summary · context
Children with MIS-C were treated with larazotide as an adjuvant to steroid/intravenous immunoglobulin therapy.
Summary · context
Outcomes were compared with children with MIS-C receiving steroids and/or IVIG therapy alone.
Summary · context
Four children with MIS-C, ages 3-17 years, were enrolled.
Summary · context
Patients were treated with open label larazotide 10 mcg/kg (maximum 500 mcg/dose) orally four times daily for 21 days.
Report a problemFND-3521168304
03HumanCase report or seriesEfficacy outcome
Children with MIS-C receiving adjunctive larazotide showed a trend toward shorter stays than children receiving steroids and/or IVIG alone.
In plain wordsChildren with MIS-C receiving adjunctive larazotide showed a trend toward shorter stays than those receiving steroids and/or IVIG alone.
Peptide
Larazotide
Outcome
DecreaseLength of stay
Study
n = 26
Comparator
Steroids and/or IVIG alone
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
10 mcg/kg (maximum 500 mcg/dose), four times daily · oral · 21 daysAs given in this study (human).
Source sentences
Summary
plus a trend towards shorter length of stay.
4 context sentences(design, population, supporting numbers)
Summary · context
Children with MIS-C were treated with larazotide as an adjuvant to steroid/intravenous immunoglobulin therapy.
Summary · context
Outcomes were compared with children with MIS-C receiving steroids and/or IVIG therapy alone.
Summary · context
Four children with MIS-C, ages 3-17 years, were enrolled.
Summary · context
Patients were treated with open label larazotide 10 mcg/kg (maximum 500 mcg/dose) orally four times daily for 21 days.
Report a problemFND-3521168305
04HumanCase report or seriesSafety outcome
Four children with MIS-C given larazotide as an adjuvant to steroid and/or intravenous immunoglobulin therapy tolerated it without adverse effects.
In plain wordsFour children with MIS-C given larazotide on top of their usual treatment had no reported adverse effects.
Peptide
Larazotide
Outcome
Not applicableAdverse effects
Study
n = 4
Outcome group
Adverse events · Whole body
Studied dose
10 mcg/kg (maximum 500 mcg/dose), four times daily · oral · 21 daysAs given in this study (human).
Source sentences
Summary
All four patients tolerated larazotide without adverse effects and displayed reduction in Spike antigenemia to undetectable levels.
4 context sentences(design, population, supporting numbers)
Summary · context
Children with MIS-C were treated with larazotide as an adjuvant to steroid/intravenous immunoglobulin therapy.
Summary · context
Outcomes were compared with children with MIS-C receiving steroids and/or IVIG therapy alone.
Summary · context
Four children with MIS-C, ages 3-17 years, were enrolled.
Summary · context
Patients were treated with open label larazotide 10 mcg/kg (maximum 500 mcg/dose) orally four times daily for 21 days.
Report a problemFND-3521168301

Studies that did not test the peptide alone1

In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Larazotide.

05HumanNot a test of Larazotide aloneCase report or seriesEfficacy outcome
In four children with MIS-C, Spike antigenemia decreased to undetectable levels during larazotide with steroid/intravenous immunoglobulin therapy.
In plain wordsIn four children with MIS-C, Spike antigen became undetectable during larazotide with steroid/intravenous immunoglobulin therapy.
Peptide
Larazotide
Outcome
DecreaseSpike antigenemia
Study
n = 4
Outcome group
Antiviral activity · Infection
Source sentences
Summary
All four patients tolerated larazotide without adverse effects and displayed reduction in Spike antigenemia to undetectable levels.
4 context sentences(design, population, supporting numbers)
Summary · context
Children with MIS-C were treated with larazotide as an adjuvant to steroid/intravenous immunoglobulin therapy.
Summary · context
Outcomes were compared with children with MIS-C receiving steroids and/or IVIG therapy alone.
Summary · context
Four children with MIS-C, ages 3-17 years, were enrolled.
Summary · context
Patients were treated with open label larazotide 10 mcg/kg (maximum 500 mcg/dose) orally four times daily for 21 days.
In this study, Larazotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Larazotide.
Report a problemFND-3521168302

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.